Orphan drug market to double as Pharma rethinks business model

The global orphan drug market is expected to double between 2016 and 2022 to $209bn as Pharma rethinks its business model away from blockbusters towards niche patient populations and orphan diseases, according to a new report.

A combination of drivers, including market saturation, pricing pressures and stricter reimbursement criteria, in addition to generic/biosimilar competition has forced Pharma to shift focus, according to the Epi Analyzer report by intelligence provider Evaluate.

To read the full article, please click on the following link: https://www.drugtargetreview.com/news/24360/orphan-drug-market-double/